Search Results - "Millar, Hillary"

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis by Vijayaraghavan, Smruthi, Lipfert, Lorraine, Chevalier, Kristen, Bushey, Barbara S., Henley, Benjamin, Lenhart, Ryan, Sendecki, Jocelyn, Beqiri, Marilda, Millar, Hillary J., Packman, Kathryn, Lorenzi, Matthew V., Laquerre, Sylvie, Moores, Sheri L.

“…Small molecule inhibitors targeting mutant EGFR are standard of care in non–small cell lung cancer (NSCLC), but acquired resistance invariably develops through…”
Get full text

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity by Brehmer, Dirk, Beke, Lijs, Wu, Tongfei, Millar, Hillary J, Moy, Christopher, Sun, Weimei, Mannens, Geert, Pande, Vineet, Boeckx, An, van Heerde, Erika, Nys, Thomas, Gustin, Emmanuel M, Verbist, Bie, Zhou, Longen, Fan, Yue, Bhargava, Vipul, Safabakhsh, Pegah, Vinken, Petra, Verhulst, Tinne, Gilbert, Angelique, Rai, Sumit, Graubert, Timothy A, Pastore, Friederike, Fiore, Danilo, Gu, Junchen, Johnson, Amy, Philippar, Ulrike, Morschhäuser, Barbara, Walker, David, De Lange, Desiree, Keersmaekers, Vikki, Viellevoye, Marcel, Diels, Gaston, Schepens, Wim, Thuring, Jan Willem, Meerpoel, Lieven, Packman, Kathryn, Lorenzi, Matthew V, Laquerre, Sylvie

“…The protein arginine methyltransferase 5 (PRMT5) methylates a variety of proteins involved in splicing, multiple signal transduction pathways, epigenetic…”
Get full text

Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases by YI TANG, NAKADA, Marian T, KESAVAN, Prabakaran, MCCABE, Francis, MILLAR, Hillary, RAFFERTY, Patricia, BUGELSKI, Peter, LI YAN

“…Matrix metalloproteinases (MMPs) are endopeptidases that play pivotal roles in promoting tumor disease progression, including tumor angiogenesis. In many solid…”
Get full text

Regulation of Vascular Endothelial Growth Factor Expression by EMMPRIN via the PI3K-Akt Signaling Pathway by Tang, Yi, Nakada, Marian T, Rafferty, Patricia, Laraio, Jenny, McCabe, Francis L, Millar, Hillary, Cunningham, Mark, Snyder, Linda A, Bugelski, Peter, Yan, Li

“…Extracellular matrix metalloproteinase (MMP) inducer (EMMPRIN) is a cell surface glycoprotein overexpressed in many solid tumors. In addition to its ability to…”
Get full text

CNTO 859, a humanized anti‐tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models by Ngo, Cam V., Picha, Kristen, McCabe, Francis, Millar, Hillary, Tawadros, Richard, Tam, Susan H., Nakada, Marian T., Anderson, G. Mark

“…Thromboembolic complications are frequently associated with advanced cancer. Interestingly, one of the major initiators of blood coagulation, tissue factor…”
Get full text

Circulating Human Interleukin-8 as an Indicator of Cancer Progression in a Nude Rat Orthotopic Human Non–Small Cell Lung Carcinoma Model by MILLAR, Hillary J, NEMETH, Jeffrey A, MCCABE, Francis L, PIKOUNIS, Bill, WICKSTROM, Eric

“…Clinically relevant animal models of human cancer are necessary for the evaluation of putative therapeutics. We hypothesized that circulating human lung…”
Get full text

αv Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models by QIMING CHEN, MILLAR, Hillary J, ANDERSON, G. Mark, MCCABE, Francis L, MANNING, Carol D, STEEVES, Rita, LAI, Kate, KELLOGG, Brenda, LUTZ, Robert J, TRIKHA, Mohit, NAKADA, Marian T

“…Purpose: Targeted delivery of cytotoxic agents to solid tumors through cell surface antigens can potentially reduce systemic toxicity and increase the efficacy…”
Get full text

Abstract 5651: JNJ-61186372, an Fc enhanced EGFR/cMet bispecific antibody, mediates EGFR and cMet downmodulation and therapeutic efficacy preclinically through monocyte / macrophage mediated trogocytosis by Vijayaraghavan, Smruthi, Lipfert, Lorraine, Bushey, Barbara, Chevalier, Kristen, Henley, Benjamin, Lenhart, Ryan, Beqiri, Marilda, Millar, Hillary J., Packman, Kathryn, Lorenzi, Matthew V., Laquerre, Sylvie, Moores, Sheri

“…Small molecule inhibitors targeting EGFR are now standard of care in NSCLC patients harboring EGFR mutations, but acquired resistance invariably develops…”
Get full text

Abstract 3905: Translational efficacy and safety modeling and simulation to support the clinical development of JNJ-64619178, a PRMT5 inhibitor by Guo, Yue, Haddish-Berhane, Nahor, Millar, Hillary J., Verhulst, Tinne, Greway, Tony, Zhou, Junguo, DeZwart, Loeckie, Gaffney, Dana, Portale, Joseph, Brehmer, Dirk, Boeckx, An, Heerde, Erika Van, Ouellet, Daniele

“…Protein arginine methyltransferase 5 (PRMT5) is an epigenetic enzyme with oncogenic properties. JNJ-64619178 (JNJ178) is a potent, selective, structurally…”
Get full text

Abstract 950: In vivo efficacy and pharmacodynamic modulation of JNJ-64619178, a selective PRMT5 inhibitor, in human lung and hematologic preclinical models by Millar, Hillary J., Brehmer, Dirk, Verhulst, Tinne, Haddish-Berhane, Nahor, Greway, Tony, Gaffney, Dana, Boeckx, An, Heerde, Erika Van, Nys, Thomas, Portale, Joseph, Philippar, Ulrike, Wu, Tongfei, Laquerre, Sylvie, Packman, Kathryn

“…Protein arginine methyltransferase 5 (PRMT5), a type II methyltransferase, is responsible for symmetric arginine di-methylation of multiple cellular proteins…”
Get full text

Abstract 36: The discovery of a novel CD19xCD22 dual-targeting CAR for the development of an IPSC-derived cell therapy by Carton, Jill M., Wheeler, John, Dower, Chris, Campion, Liam, Millar, Hillary J., Beqiri, Marilda, Morse, Barry, Gurung, Buddha, Genovese, Rebecca, DeLuca, Steven, Dominick, Charles, Naso, Michael, Levitsky, Hy

“…Dual-targeting cell therapies to address CD19 antigen loss in heme malignancies are being explored by Century Therapeutics and others for unmet clinical need…”
Get full text

Abstract 4859: JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models by Wu, Tongfei, Millar, Hillary, Gaffney, Dana, Beke, Lijs, Mannens, Geert, Vinken, Petra, Sommers, Ivan, Thuring, Jan-Willem, Sun, Weimei, Moy, Christopher, Pande, Vineet, Zhou, Junguo, Haddish-Berhane, Nahor, Salvati, Mark, Laquerre, Sylvie, Lorenzi, Matthew V., Brehmer, Dirk

“…PRMT5 is a type II methyltransferase that symmetrically di-methylates arginine residues on proteins involved in signal transduction and cellular transcription…”
Get full text

Abstract 6802: CXCR4 transgene improves in vivo migration and efficacy of engineered iPSC-derived natural killer cells by Millar, Hillary J., Walker, David, Campion, Liam R., Budd, Ciara, Kolluri, Aarti, Sharma, Harsh, Gurung, Buddha, Carton, Jill M., Perry, Daniel J., Alexander, Nicholas, Levitsky, Hyam, Naso, Michael, Morse, Barry A.

“…Chimeric antigen receptor (CAR)-engineered induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells have shown a favorable safety profile and…”
Get full text

Abstract 1916: Discovery of a novel Nectin4 IPSC-derived cell therapy for the treatment of solid tumors by Carton, Jill M., Dower, Chris, Miller, Michael, Wheeler, John, Heron, Sean, Millar, Hillary J., Walker, David, Perry, Daniel J., Lebid, Andriana, Cocka, Luis, Kim, Dae Hwan, Morse, Barry, Gurung, Buddha, Harris, Maisha, Jethon, Annalise, Naso, Michael, Levitsky, Hy

“…Century Therapeutics is developing a Nectin4-targeting IPSC-derived cell therapy for the treatment of Nectin4 expressing solid tumors. The Nectin proteins…”
Get full text

Abstract 1492: Development of a CD123xCD3 bispecific antibody to treat acute myeloid leukemia (AML) by Gaudet, Francois, Nemeth, Jennifer F., McDaid, Ronan, Li, Yingzhe, Harman, Benjamin, Millar, Hillary, Teplyakov, Alexey, Wheeler, John, Luo, Jinquan, Tam, Susan, Wu, Sheng-Jiun, Chen, Emily, Babich, Alexander, Elsayed, Yusri, Attar, Ricardo

“…AML is a heterogeneous disease characterized by uncontrolled clonal expansion of leukemic stem cells (LSCs). Current therapies for AML are not curative, in…”
Get full text

Abstract 4199: Inhibition of NF-kB inducing kinase (NIK) selectively abrogates NIK and TRAF3 mutant multiple myeloma tumor growth by Versele, Matthias, Janssen, Lut, Geerts, Tamara, Floren, Wim, Janssens, Boudewijn, Millar, Hillary, Jacoby, Edgar, Gross, Gerhard, Ligny, Yannick, Simonnet, Yvan, Amblard, Nathalie, Querolle, Olivier, Csoka, Imre, Poncelet, Virginie, Tronel, Virginie, Nocquet-Thibault, Sophie, Meerpoel, Lieven, Edwards, James, Salvati, Marc, Balasubramanian, Sriram, Lenox, Laurie, Theuer, Charles, Attar, Ricardo, Stansfield, Ian

“…Enhanced NF-kB signaling is a hallmark of aggressive lymphoid malignancies, including multiple myeloma (MM), mantle cell lymphoma (MCL), and diffuse large…”
Get full text

Development of a CD123xCD3 Bispecific Antibody (JNJ-63709178) for the Treatment of Acute Myeloid Leukemia (AML) by Gaudet, François, Nemeth, Jennifer F, McDaid, Ronan, Li, Yingzhe, Harman, Benjamin, Millar, Hillary, Teplyakov, Alexey, Wheeler, John, Luo, Jinquan, Tam, Susan, Wu, Sheng-Jiun, Chen, Emily, Rudnick, Stephen, Chu, Gerald, Hughes, Anna, Luistro, Leopoldo, Chin, Diana, Babich, Alexander, Kalota, Anna, Singh, Indrajeet, Salvati, Mark, Elsayed, Yusri, Attar, Ricardo M.

“…AML is a cancer of the myeloid lineage that is characterized by the accumulation of abnormal white blood cells in the bone marrow and blood. Existing therapies…”
Get full text

Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models by Brehmer, Dirk, Wu, Tongfei, Mannens, Geert, Beke, Lijs, Vinken, Petra, Gaffney, Dana, Sun, Weimei, Pande, Vineet, Thuring, Jan-Willem, Millar, Hillary, Poggesi, Italo, Somers, Ivan, Boeckx, An, Parade, Marc, Heerde, Erika van, Nys, Thomas, Yanovich, Carol, Herkert, Barbara, Verhulst, Tinne, Jardin, Marc Du, Meerpoel, Lieven, Moy, Christopher, Diels, Gaston, Viellevoye, Marcel, Schepens, Wim, Poncelet, Alain, Linders, Joannes T., Lawson, Edward C., Edwards, James P., Chetty, Dushen, Laquerre, Sylvie, Lorenzi, Matthew V.

“…PRMT5 is a type II methyltransferase that specifically adds methyl groups to arginine as a long-lasting post-translational modification. The PRMT5/MEP50…”
Get full text

CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells by Chen, Qiming, Manning, Carol D., Millar, Hillary, McCabe, Francis L., Ferrante, Catherine, Sharp, Celia, Shahied-Arruda, Lillian, Doshi, Parul, Nakada, Marian T., Anderson, G. Mark

“…CNTO 95 is a fully human monoclonal antibody that recognizes αv integrins. Previous studies have shown that CNTO 95 exhibits both anti-tumor and…”
Get full text

Abstract C189: CD24 plays an important role on NSCLC cell functions relevant to tumor growth by Macedo, Luciana F., Kaiser, Elizabeth, Jiang, Haiyan, Millar, Hillary, Pietsch, E. Christine, Kaplan, Fred, Wiley, Diana, Snyder, Linda A., Marshall, Debbie

“…CD24 is a heavily glycosylated glycosylphosphatidylinositol-anchored protein that is over-expressed in many different tumor types including lung cancer (NSCLC…”
Get full text